A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Mosunetuzumab (Primary) ; Tocilizumab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Roche
- 04 Dec 2023 Study design is changed from single-group assignment to parallel. Number of treatment arms increased from 1 to 3 by the addition of Arms B and C, where mosunetuzumab in combination with venetoclax is used in the regimen of arm C. Timeline for primary end-point for Arm-C is added as 24 months.
- 04 Dec 2023 Planned number of patients changed from 56 to 137.
- 04 Dec 2023 Planned End Date changed from 31 Jul 2027 to 8 Oct 2029.